Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  epirubicin hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 89 for your search:
Start Over
A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: LITE Randomized Pilot Study, NCT00531973
Yunzhi as Dietary Supplement in Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: YUNZHI-BC, NCT00647075
Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: BCP06, NCT01199432
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P0334, NCT01501487
Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: BEST T-01, NCT01849380
A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
Phase: Phase IV
Type: Treatment
Status: Active
Age: Under 66
Sponsor: Other
Protocol IDs: PAD VS VCD Clinical Protocol, NCT01868828
Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CIH-TZS-20140421-02, NCT02207361
Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AEl-Sawy172014, NCT02214602
Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000536013, MRC-ST03, EU-20710, ISRCTN46020948, 2006-000811-12, 00316/0221/001, EUDRACT-2006-000811-12, CTA-00316/0221/001, NCT00450203
Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 20 to 79
Sponsor: Other
Protocol IDs: ACE500, NCT00843934
Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: R-09-025, NCT00907543
Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000675485, PACT-15, 2010-019942-23, SRSI-PACT-15, EU-21040, NCT01150630
Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 2011_25, 2012-000998-24, NCT01717924
ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: WSG-AM06 / ADAPT HR+/HER2-, NCT01779206
The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GC-COMB-0254/275/2012-MUL, GC-0254/282/2011/275/2012-MUL, NCT01787539
A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: HBMUFH-101, NCT01907529
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AG0407GR, ACTRN12609000035224, U1111-1146-0762, TROG 08.08, 22114-40111, GA.1, NCT01924819
The Efficacy and Safety of Retreatment With Transarterial Chemoembolization (TACE) for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: HCC201408, NCT02220088
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR005143, EPOANE3010, 2005-001817-17, NCT00338286
Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRITICS, NCT00407186
Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: DSMM V, NCT00546988
Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 20
Sponsor: Other
Protocol IDs: 200803006M, NCT00776724
Regimens Comparison for Breast Cancers of Positive Lymph Nodes
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: CH-BC-006, NCT01134523
Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CH-BC-007, NCT01150513
Start Over